Considering the associated risk of infection and cardiovascular complications, splenectomy is being replaced by immunosuppressive agents and thrombopoietin receptor agonists (TPO-RAs) as the second-line treatment of ITP [10]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.